



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/987,930	11/16/2001	Thomas P. Jerussi	4821-438-999	7891

20582 7590 09/11/2006

JONES DAY

51 Louisiana Avenue N.W.

Washington, DC 20001-2113

EXAMINER

KIM, VICKIE Y

ART UNIT

PAPER NUMBER

1618

DATE MAILED: 09/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/987,930

Applicant(s)

JERUSSI ET AL.

Examiner

Vickie Kim

Art Unit

1618

– The MAILING DATE of this communication appears on the cover sheet with the correspondence address –
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 13-15 and 58-78 is/are pending in the application.
- 4a) Of the above claim(s) 60, 68 and 70-75 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 13-15, 58-59, 61-67, 69, 76-78 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____.
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: ____.

DETAILED ACTION

Status of Application

1. Acknowledgement is made of amendment filed 7/5/06. Upon entering the amendment, the claims 13 and 60 are amended.
2. Claims 13-15, 58-78 are now pending. The elected claims 13-15, 58-59, 61-67, 69, 76-78 have been examined only to the extent that they read on use of the elected species in the claimed method. All remaining(or portions thereof) not drawn to the elected species are withdrawn from further consideration as being non-elected. The following rejections are made.
3. A confusing statement on finality of previous office action is clarified thru telephonic communication on 8/29/06, see interview summary(PTO-413) attached.

Response to Arguments

4. Applicant's arguments filed 7/5/06 have been fully considered but they are not persuasive.

Claim Rejections - 35 USC § 112, 1st

Applicant amended the claims 13 and 60 to obviate 112, 1st (Scope of Enablement) rejection. However, it fails to delete the phrase "prophylactically effective amount" in claim 13 and 60. Ands thus, the claims are not enabled for the very same reasons set forth in previous office action mailed 3/1/2006(see below).

Claim Rejection-103Rejection

It is noted that the introduction included incorrect title (i.e. 102 rejection) instead of 103 rejection. However, it is readily apparent to applicant that the 102 title is inadvertent typographical error since the context of rejection is obviously written with 103 format. Thus, the correction is made, and the 102(e) rejection is replaced with 103 rejection hereinafter.

Applicant argues that Young et al's reference is not prior art under 103(c). Thus, Young et al's reference is deleted and the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Simeon and Morgan(see below).

Claim Rejections - 35 USC § 112, 1st

Scope of Enablement

1. claims 13-15, 58-59, 61-67, 69, 76-78 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims because the specification, while being enabling for TREATING or reducing the occurrence of affective disorder(e.g. anxiety disorder) in a patient in need thereof using a therapeutically effective amount of a bupropion metabolite, does not reasonably provide enablement for utilizing prophylactically effective amount to treat said affective disorders as claimed.

Without knowing how to prevent the disease, one skilled in the art would have not enable to make an prophylactically effective amount of drug and to use the invention commensurate in scope with these claims.

The detailed 112, 1st rejection is substantially same as the one mentioned in office action mailed 3/1/2006.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 13-15, 58-59, 61-67, 69, 76-78 are rejected under 35 U.S.C. 103 as being unpatentable over Simeon et al(1986, Bupropion effects...) in view of Morgan (US6391875, 6274579, 2003/0064988).

*** Note: all these patents are children cases of US6274579, and disclosures therein are substantially same. Therefore, the examiner will use US'579 to represent all these cases.

The claims are drawn to a method of treating or preventing an affective disorders (e.g. anxiety disorder) by administering a therapeutically or prophylactically effective amount of (2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol (or salt, solvates thereof) as a bupropion metabolite.

Simeon et al teach bupropion shows significant improvements of anxiety, hyperactivity(attention deficit disorders), conduct disorder, etc, see abstract.

Art Unit: 1618

Applicant's claims differ because they require bupropion's metabolite, (2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol.

However, it would have been obvious to one of ordinary skill in the art at that time of the invention was made to employ bupropion metabolite (i.e. 2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol) instead of bupropion to treat anxiety when Simeon et al is taken in view of Morgan's patent because Morgan teaches that (2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol) is active metabolite of bupropion and also proves the efficacy against affective disorders such as attention deficit disorders, etc.

Morgan et al (US'579) teaches a compound (2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol as active metabolite of bupropion and its composition used for various psychogenic disorders such as depression or addiction, see abstract and col.2, lines 21-63 and col.5, lines 36-52. Furthermore, it teaches that other activities (other conditions not mentioned in the patent) of Wellbutrin® (bupropion) could be attributed to the compound, (2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, see col.8, lines 4-15. Since it is metabolite of bupropion, the efficacy of the compound should be significantly higher than bupropion (see col.9, table 1).

One would have motivated to use bupropion metabolite to treat anxiety, with reasonable expectation of success, because bupropion and its metabolites utilize same pathways to obtain same pharmacological activity but also the improved therapeutic effectiveness and safety are well proven and thus one would have increase industrial

applicability by reduction of side-effects(due to lower dose used for the same outcome), etc.

One would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities, and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

The effective dosage regimen(see col.5, lines 40-45), formulations(from col.5, lines 63 to col.6, lines25) and routes of administration(col.5, lines 59-62) are well taught by Morgan's patent and thus, the dependent claims 61-67 are properly included in this rejection.

US579 also teaches pure enantiomers and racemates, see col 3, lines 10-15.

Conclusion

6. No claim is allowed.


THIS ACTION IS 2nd non- final rejection.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



VICKIE KIM
PRIMARY EXAMINER

Vickie Kim
Primary Patent Examiner
September 1, 2006
Art unit 1618